253
Views
2
CrossRef citations to date
0
Altmetric
Original research

The effects of atorvastatin and rosuvastatin on exercise tolerance in patients with coronary heart disease

, , , , , , , & show all
Pages 1203-1208 | Received 19 Dec 2019, Accepted 19 Jun 2020, Published online: 02 Jul 2020
 

ABSTRACT

Objectives

This study was aimed to analyze the effects of atorvastatin and rosuvastatin and different lipid-lowering intensity treatments on exercise tolerance in patients with coronary heart disease (CHD).

Methods

A retrospective analysis was conducted in 549 patients with CHD who underwent cardiopulmonary exercise testing (CPET) from February 2014 to August 2018. The CPET results of patients taking different types and doses of statins were compared from baseline to follow-up.

Results

No significant difference was found in baseline VO2peak between the rosuvastatin group and the atorvastatin group. The VO2peak growth of the rosuvastatin group was significantly greater than that of the atorvastatin group after treatment [1.52 ± 4.03 ml/kg/min vs 0.90 ml/kg/min (−1.60, 3.45), p = 0.018]. Multivariate analysis showed that atorvastatin was a negative independent influencing factor of ΔVO2peak (B = −0.665, SE = 0.321, t = −2.070, p = 0.039, 95% CI: – 1.295~-0.034). There was no significant difference between the median intensity and high-intensity lipid-lowering groups in parameters of CPET.

Conclusions

The exercise tolerance improvement was more considerable for patients with CHD taking rosuvastatin compared with those taking atorvastatin. The lipid-lowering intensity of statins was not independently associated with changes in exercise tolerance in patients with CHD.

Author contributions

Conception and design: Wei Gao, Wei Zhao and Shunlin Xu. Analysis and interpretation of the data: Dan Liu, Tao Shen, Chuan Ren, Lequn Zhou, Jin Bai and Nan Li. Drafting of the paper: Dan Liu and Tao Shen. Revising it critically for intellectual content: Wei Zhao and Wei Gao. Final approval of the version to be published: Wei Gao.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was funded by the National Key R&D Program of China (2017YFC0908700), the National Natural Science Foundation of China (81601968) and the Clinical Scientist Fund of XinXin Heart (SIP)Foundation–China Cardiovascular Association (NO. CCA-CSMVP-1710).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.